News
Novo Nordisk beefs up in oral obesity drugs with Vivtex deal
Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
News
GSK grows pipeline with 35Pharma takeover, Frontier deal
GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.
News
Astellas bets on Vir cancer drug, and other licensing deals
Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
R&D
Results, reality, and recalibration: Unpacking AI hype at SC...
SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
News
After CagriSema blow, Novo reveals data for obesity 'triple'
Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
